• Expert recommendations focused on the diagnosis and management of genital psoriasis across age groups including pediatric, adult, and older populations
  • This is the second published manuscript from the Genital Psoriasis Wellness Consortium, a multidisciplinary group of expert clinicians
  • Genital involvement occurs in approximately two-thirds of the nine million individuals with plaque psoriasis in the United States

     

WESTLAKE VILLAGE, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the publication of a new manuscript in the American Journal of Clinical Dermatology by the Genital Psoriasis Wellness Consortium. This second publication from the Consortium builds upon prior consensus work by providing healthcare providers with clinically practical, expert-driven guidance to help improve the recognition, diagnosis, and management of genital psoriasis across pediatric, adult, and older populations.

The paper emphasizes the importance of routine assessment, empathetic communication, and age-appropriate, individualized treatment approaches to address persistent gaps in care for this under-recognized and under-treated aspect of the condition. The guidance is organized by demographic group rather than overarching themes, offering meaningful, real-world value and ease of application for clinicians treating individuals with this chronic inflammatory skin condition.